Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 study.
- Home |
- Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
- February 26, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
